KR101432746B1 - Mixture extract of yacon(Smallanthus sonchifolius), Torilis japonica and Acorus gramineus, health food composition and cosmetic composition for preventing or improving benign prostatic hyperplasia or alopecia containing the same - Google Patents

Abstract

The present invention relates to a health food composition for preventing or ameliorating alopecia or enlargement of the prostate gland comprising a mixed extract of yacon, casualties and seokchangpo and an effective ingredient thereof, and a cosmetic composition for preventing or improving hair loss. The mixed extracts of yacon, casualties, and seokchangpo according to the present invention have an excellent effect on the inhibition of testosterone 5? -Reductase, and thus can be effectively used as a health food composition or a cosmetic composition for prevention and improvement of prostate enlargement as well as hair loss. It was confirmed that the urine of the patients with hypertrophy of prostate after 1 to 2 weeks of administration of the mixed extract according to the present invention, urinary frequency, nocturia, nocturia, urine, oliguria and urinary incontinence symptoms were improved. Further, administration of the mixed extract according to the present invention promoted liver fat metabolism and improved renal function. In addition, even when the mixed extract according to the present invention is taken for a long period of 12 months or more, unlike conventional chemical agents, there is no case of adverse side effects or inconvenience due to taking, and safety is excellent.

Description

[0001] The present invention relates to a health food composition for preventing or ameliorating a mixed extract of yacon, casualties, and astringency, a hair loss or prostate enlargement containing the same, and a cosmetic composition for preventing or improving hair loss, food composition and cosmetic composition for preventing or improving benign prostatic hyperplasia or alopecia containing the same}

The present invention relates to a health food composition for preventing or ameliorating alopecia or enlargement of the prostate gland comprising a mixed extract of yacon, casualties, and seokchangpo and an effective ingredient thereof, and a cosmetic composition for preventing or improving hair loss.

The role of sex hormones in our bodies is very important. Androgens, the male hormones, are synthesized in the adrenocortical and gonadal lines. Representative ones are testosterone and DHT (dihydrotestosterone). Testosterone is involved in the increase of muscle mass, the growth of the penis and scrotum, the voice change, the masculine conspiracy and armpit hair, and spermatogenesis, and DHT is involved in the growth of the prostate, acne and leprosy (chest, whiskers, limbs, torso, ), Androgenic alopecia. Therefore, although testosterone is essential for normal male functions such as maleisation and spermatogenesis, DHT is not essential except for the birth of gonads at the time of birth, and DHT causes many diseases such as enlarged prostate, acne, hirsutism, and androgenetic alopecia In the medical field, attempts have been made to inhibit DHT production by inhibiting 5α-reductase, an enzyme that converts testosterone to DHT.

There are two types of 5α-reductase (type 1 and type 2), both enzymes that convert testosterone to DHT. Type 1 is mainly found in the sebaceous glands, epidermis, keratinocytes, dermal papilla cells, and sweat glands. Type 2 is the root sheaths of the scalp hair follicles, epididymas, vas deferens, seminal vesicles, It is mainly distributed in the skin of the prostate and fetal genitalia.

The 5α-reductase is present in both hair follicles of type 1 and type 2, and both type 1 and type 5α-reductase are expressed in the outer root sheath of patients with androgenetic alopecia. Suppression of allelic enzymes has the potential to treat androgenetic alopecia. In people with congenital deficiency of 5α-reductase type 2, there is no androgenetic alopecia, or the forehead line is slightly backward. In the sebaceous glands, epidermis, and sweat glands, 5α-reductase type 1 is involved in the formation of DHT. Therefore, in the case of acne, it is effective to specifically inhibit type 1 5α-reductase enzyme.

The sebaceous gland is a place to make sebaceous glands that supply oil to the skin and the surface of the skin. It is located at the top of the skin's forehead and is connected to the hair follicles. The sebaceous glands are distributed throughout the body except the palms and soles, and are most distributed in the head and face. The lipid and sebum, similar to the oil produced here, is transported through the sebaceous gland into the hair follicle and then drained out of the skin along the hair. As puberty enters the sebaceous glands, the sebaceous glands become more active, and the free fatty acids produced by the action of germs in the hair follicles play an important role in the development of acne. The sebaceous glands secrete type 1 5α-reductase. This enzyme reduces testosterone, the male hormone, to 5α-DHT, inhibiting the division of mosquito cells and preventing the production of hair. When the sebaceous gland is enlarged and function is active, not only is there a lot of dandruff on the surface of the hair, but also the secretion of this reductase increases, affecting hair growth and growth. Therefore, the sebaceous glands of people with baldness are generally overgrown, whereas those with abnormally hairy or hirsutism have normal or slightly smaller sebaceous glands.

The prostate is one of the sexually transmitted organs that function together with the seminal vesicles and the testes. It is located in the lower part of the bladder and passes through the center of the prostate and the urethra. It is about 4 ~ 5cm in size and weighs about 20g. The prostate makes part of the sperm, the prostate fluid. The prostate fluid nourishes the sperm and improves the mobility of the sperm by enhancing the motility of the sperm so that the sperm is not hardened. In addition, the prostate fluid is alkaline, neutralizing the strong acidity of the fallopian tube, sperm safely through the fallopian tube to meet with the egg to help the correction is also played a role.

If a prostate abnormality occurs, it causes great obstacles in urination and sexual life. Especially in Korea, prostate-related diseases such as prostatitis, enlargement of the prostate and prostate cancer are increasing due to westernized diet and lifestyle.

It is known that testosterone enters the prostate tissue in the blood, transforming it into DHT by the action of 5α-reductase, bind to the receptor in the prostate cell, and proliferate and proliferate at the same time.

Treatment of prostate hypertrophy is largely divided into 5α-reductase inhibitors, antihypertensive agents, and drugs that open the prostate urethra (α-blockers), drugs that reduce prostate size. Commercially available 5α-reductase inhibitors include 'finasteride' that suppresses only type 2 and 'dutasteride' that suppresses both. The chemically synthesized 5α-reductase inhibitors finasteride, dutasteride, and the like, inhibit changes in male hormone (testosterone), which plays an important role in sexual desire and erectile function, into a stronger form (DHT) Adverse effects, such as decreased sexual desire and decreased amount of ejaculation have been reported.

There are two types of 5α-reductase that convert testosterone into DHT. Type 1 is known to be present in the brain, liver, skin other than genitalia, skin protrusions of hair follicles, and type 2 is the prostate, epididymis, seminal vesicles It is present in the androgen-dependent tissues and is associated with prostatic hyperplasia. Thus, the 5α-reductase is also present in the brain and plays an important role in the function of neurons and central nervous system. This enzyme inhibits the hypothalamic-pituitary-testicular hormone axis is damaged, sexual desire and sexual function are suppressed side effects and testosterone production And erectile dysfunction appears.

Therefore, efforts have been made to prevent or ameliorate hair loss and enlargement of the prostate using a natural product-derived 5? -Reductase inhibitor without such side effects. For example, a health functional food (Patent Registration No. 10-0521800) for prevention and improvement of alopecia and seborrheic dermatitis containing Daruai extract, a pomegranate extract for preventing hair loss, and a cosmetic composition for preventing hair loss including the above pomegranate extract (Patent Registration No. 10-0500641), an oral composition for treating scalp disorders (Patent Registration No. 10-0846888), a composition for preventing hair growth or hair growth comprising isoflavone aglycon genistein A cosmetic composition for preventing hair loss and improving hair growth containing stem extract as an active ingredient (Patent Registration No. 10-0927971) and the like are known.

Smallanthus sonchifolius is a perennial plant belonging to the family Asteraceae (Compositae). Its origin is Ecuador, Peru in the Andes region of South America, and it has been used as food and folk medicine by the Indians in the high mountain region. In Korea, Has been cultivated all over the country now.

Water soluble extracts of yacon leaves have been reported to lower blood glucose levels in rats (J. Ethnopharm., 125-132, 2001). Chlorogenic acid, Caffeic acid, and ferulic acid, and has been reported to be effective as a preventive and therapeutic agent for chronic diseases caused by active radicals (Eur. J. Nutr , 42: 61-66, 2003; J. Agric. Food Chem., 53: 5577-5582, 2005).

And the yacon roots are similar in appearance to sweet potatoes, and taste is sweet and cool. The yacon rootstock contains a large amount of phenolic compounds and fructo-oligo sugar (Natural Product Science, 14: 73-80, 2008; Field Crops Res., 86: 157-165, 2004) (Eur. J. Nutr. 42: 61-66, 2003; Yakugaku Zasshi, 126 (8), 665-669.) In Japan, it has already been used as a dietary supplement for people suffering from diabetes mellitus. , 2006).

 Yacon contains carbohydrates such as fructose, glucose, sucrose, fructooligosaccharide and inulin in large amounts, and contains no starch. Among them, fructooligosaccharide is a non-toxic sweet substance, which is fed to Bifidus, a lactic acid bacterium in the intestines, which promotes digestion and improves intestinal flora. In particular, fructose contained in yacon is 1.5 to 2.0 times higher in sugar content than sucrose, which is used as a major sweetener, has a slow absorption rate in the intestines, and is not easily absorbed and utilized in the body, And the like.

 In addition, the yacon rootlets contain more alkaline elements than other vegetables and fruits and contain 21 kinds of free nitrogen compounds. Among them, amino acids and amides such as asparagine, glutamine, proline and arginine are relatively abundant .

Casualties use mature fruits of 1 - year - old or perennial herbivorous herbivorous herbivorous species belonging to the Umbaliferae family, and related plants, and the mature fruit of Torilis japonica is used in our country. It grows naturally in riverside, beaches, valleys in mountain streams and mountains, and mature fruits are harvested in both spring and autumn seasons and dried in the sun. The mature nature is the spicy, the bitter, the non-toxic, the kidney and the 脾. The efficacy has the efficacy such as warm kidney (阴 壯 壯 阳), humidity insecticide (燥濕 杀 虫), and live giant wind (寒 祛 祛 风) , And ameliorate the symptoms of manic episodes (itchy pruritus). The efficacy of modern medicinal casualties has been shown to have antimicrobial, antiviral and male hormone-like actions, and it has been shown to be effective in the treatment of moxibustion, impotence and uterine prolapse and skin pruritus, irritable dermatitis, acute exudative dermatitis, trichomoniasis, It is applied to various skin diseases such as dermatitis, scrotum eczema and omnidia.

Seokchangpo is a perennial herb belonging to the genus Araceae and its scientific name is Acorus gramineus. It grows naturally in the southern part of China and is cultivated. In autumn, rootstock is picked up and used after drying, and mature is in the spicy, warm, naive, heart and stomach. It has sedative, analgesic and structuric effects and is used for mental confusion, tinnitus, headache, arthritis, gastritis, duodenal ulcer, dyspepsia and chronic bronchitis. It has been found that 0.5-1.9% of the rootstock and 0.25% of the fresh leaves contain essential oils. 63 to 81% of the essential oil is β-asarone, and other essential oil components such as α-asarone 8 to 14% and kariopyrene 1 to 4% are contained. In addition, palmitic acid, phenolic substance, And so on. The pharmacological action of Seocheongpo which has been revealed so far has been used frequently in clinic for neuropsychiatric disorders because of its calming and shaking action. In other words, when the extract of Seokchangpo was injected intraperitoneally into mice, the spontaneous movement was markedly decreased and the sleeping time was prolonged. When pentylenetetrazole was intraperitoneally injected into the rats with septic shock, There was a decrease in the number of animals in the rabbits, and it was reported that acetylcholine was injected into the lateral ventricles of rabbits, In addition, oral administration of Seokchangpo extract promotes the secretion of digestive juices, inhibits abnormal fermentation of the stomach, relaxes smooth muscle spasm of the stomach, and β and α-asarone have been shown to significantly increase the coronary blood flow of guinea pig . Α-Asarone has also been shown to exert an effect on histamine-induced bronchoconstriction in cats.

Thus, the inventors of the present invention introduced a method of treating a prostate disease, which is a principle of a bilateral treatment method, namely, simultaneously administering a 5α-reductase inhibitor, a drug that reduces prostate size, and an α- As a result, it was found that the mixed extracts including yacon, casualties, and seokchangpo were effective in preventing or ameliorating hair loss and enlargement of the prostate gland without side effects, and in particular, As a result of administering the mixed extract to a person suffering from prostate hyperplasia, the present inventors have completed the present invention by finding that urine, nighttime urine, urinary incontinence, etc. are improved and the urine volume is increased once.

The present invention provides a 5α-reductase inhibitor derived from natural products and an α-amylase inhibitor which can be effectively used for preventing or improving hair loss and enlargement of the prostate without causing side effects such as erectile dysfunction, And a cosmetic composition for preventing or ameliorating alopecia. The present invention also provides a cosmetic composition for prevention or alleviation of alopecia or prostate hyperplasia.

In order to accomplish the above technical object, the present invention proposes a mixed extract of yacon, casualties and seokchangpo.

The present invention also provides a health food composition for preventing or ameliorating hair loss or enlargement of the prostate gland comprising the above-mentioned mixed extract as an active ingredient.

The present invention also provides a cosmetic composition for preventing or ameliorating hair loss comprising the above-mentioned mixed extract as an active ingredient.

The mixed extracts of yacon, casualties, and seokchangpo according to the present invention have an excellent effect on the inhibitory effect on testosterone 5? -Reductase, thereby being useful as a health food composition or cosmetic composition for prevention and improvement of prostate enlargement as well as hair loss In particular, it was confirmed that the urine, retention, nighttime urine, urine, oliguria and urinary incontinence symptoms of the patients with enlarged prostate were improved 1 to 2 weeks after administration of the mixed extract according to the present invention. Further, administration of the mixed extract according to the present invention promoted liver fat metabolism and improved renal function.

In addition, even when the mixed extract according to the present invention is taken for a long period of 12 months or more, unlike conventional chemical agents, there is no case of adverse side effects or inconvenience due to taking, and safety is excellent.

FIG. 1 shows the effect of DHT concentration on blood administration of the mixed extract prepared in Example 1 of the present invention.
2 is a Western blot result showing the effect of the mixed extract prepared in Example 1 on the expression of PCNA (proliferating cell nuclear antigen) protein.
FIG. 3 shows the results of the average prostate index according to the age distribution of the questionnaire respondents and the international prostate symptom score table (IPSS) in Experimental Example 6. FIG.
FIG. 4 is a graph showing the results of an international prostate symptom score test before and after the administration of a pill containing the mixed extract prepared in Example 2 in Experimental Example 6. FIG.

Hereinafter, the present invention will be described in detail.

The mixed extract according to the present invention is a mixed extract of yacon, casualties, and garlic, and the yacon may include at least one of yacon leaves and yacon roots.

In the present invention, the yacon, the casualties, and the seokchangpo can be used by being sold on the market.

The mixed extract according to the present invention may be one obtained by mixing yacon, casualties, and garlic cloves and extracting with an extraction solvent, or may be a mixture of single extracts obtained from each of yacon, casualties, and seokchangpo and individual extracts thereof. The mixed extract according to the present invention may be a powder or a liquid unless otherwise specified.

Meanwhile, the mixed extract according to the present invention can be produced by a known extraction method. For example, yacon, casualties, and trachea purchased from medicinal materials are finely mixed, and an extraction solvent having a volume of 10 to 15 times the volume of the mixed medicament is added. To prevent the extraction solvent from evaporating, a cooling condenser The mixture is heated and extracted at 90 to 100 ° C for 24 to 48 hours with a hot-water extractor, and the resulting extract is concentrated and concentrated using a vacuum distillation apparatus to obtain a liquid extract, or a lyophilized product, .

In this case, the mixing weight ratio of yacon, casualties and gypsum is not particularly limited, but is preferably 1 to 50: 1 to 25: 1 to 25, more preferably 1 to 4: 1 to 2: 1 to 2.

The extraction solvent is not particularly limited, and is preferably an extraction solvent such as water, ethanol, methanol, propanol, ethyl acetate or a mixed solvent thereof. Among them, water or a functional ethanol is most preferable. Here, in the case of the functional ethanol, the amount of ethanol contained therein is preferably 30 to 70 (w / w)%, more preferably 50 (w / w)%.

The thus-prepared mixed extract according to the present invention has an effect of inhibiting testosterone 5? -Reductase, and thus can be effectively used for preventing and improving androgenic alopecia and prostatitis.

In addition, the present invention provides a health food composition for prevention or amelioration of hair loss or enlargement of the prostate gland, which comprises the mixed extract of yacon, casualties and seokchangpo as an active ingredient.

At this time, it is preferable that the content of the mixed extract of yacon, casualties and seokchonpo contained in the health food composition is 60 to 80 wt% based on the total weight of the health food composition.

Meanwhile, the health food composition according to the present invention can be suitably processed in the form of pill, powder, tablet, capsule or liquid. For example, in the case of a ring form, a mixture of the mixed extract, excipient, binder, disintegrant, etc. according to the present invention can be prepared by molding in a usual manner. If necessary, the mixture may be sieved with a substance such as saccharide, The substance may be irritated.

In addition, the health food composition according to the present invention may further include a known food additive suitably determined according to the standard and standard for the relevant item in accordance with the general rules of the Food Additives Ordinance approved by the Food and Drug Administration, and the General Test Methods .

In addition, the present invention provides a cosmetic composition for preventing or ameliorating hair loss, which comprises the mixed extract of yacon, casualties, and seokchangpo as an active ingredient.

Here, the content of the mixed extracts of yacon, casualties and stonewash contained in the cosmetic composition is preferably 0.1 to 10% by weight based on the total weight of the cosmetic composition.

The formulation for the cosmetic composition according to the present invention is not particularly limited, but is preferably a cream, a shampoo or a pack, which is easy and convenient in applying to the scalp. At this time, in the cosmetic composition of each formulation, in addition to the mixed extract, a colorant, a flavoring agent, a suspending agent, an emulsifier, a dissolution aid, a stabilizer, an isotonic agent, a pH adjuster, a viscosity regulator, a solvent, .

Hereinafter, the present invention will be described in detail on the basis of embodiments. The presented embodiments are illustrative and are not intended to limit the scope of the invention.

< Example  1> Preparation of mixed extract

1 g of distilled water was added to 100 g of a mixed medicinal product consisting of 25 g of yacon leaves (Ondang Yacon Co., Ltd.), 25 g of Yaconpuri (Ondang Yacon Co., Ltd.), 25 g of casualties (EYELA FD-5N, Japan) was used to concentrate the extract to a solid content of 20% using a rotary vacuum distillation apparatus (EYELA, Japan) And dried to obtain a powdery mixed extract.

< Example  2 > Preparation of pellets containing mixed extracts

To 2 kg of mixed medicines consisting of 500 g of yacon leaves (500 g), 500 g of yaconpuri (Ondang yacon), 500 g of casualties (Kyojin Yakuhin Co., Ltd.) and 500 g of Seocheongpo The resulting filtrate was filtered through a hot-water extractor at 100 ° C for 3 hours, filtered and concentrated to 50 Brix using a rotary vacuum distillation apparatus (EYELA, Japan). The filtrate thus obtained was filtered through a filter paper (250 g, 1 kg of mixed medicines consisting of 250 g of Yakonpuri (Ondang Yacon Co., Ltd.), 250 g of casualties (Green Pharmaceutical Co., Ltd.) and 250 g of Seocheongpo Co., Ltd. Respectively.

< Experimental Example  1> S.D. Rats  Measurement of prostate hypertrophy

Animal experiments were conducted to measure the inhibitory effect of the mixed extract prepared in Example 1 on prostate hypertrophy.

The experimental animals used in this experiment were S.D. (12 weeks old, male, average body weight 350-360 g, Sam Taco Co., Ltd.) for 5 days. The environment of the breeding room and the laboratory was controlled at a temperature of 23 ± 2 ° C., a relative humidity of 55 ± 10%, a lighting cycle of 12 hours (07: 00-19: 00) and an illumination of 150-300 lux. Diets were fed a solid diet for rats, and water was allowed to drink purified water. All animal studies related to this experiment were conducted under the approval of the Center for Standard Operating Procedures (SOP) and the American Toxicological Society of Toxicology (1989) under the approval of the Institutional Animal Care and Use Committee (IACUC) Society of Toxicology, SOT).

 This experiment was conducted using a normal control group, a benign prostate hypertrophy (BPH group), a positive control group (finasteride (Hanol Pharmaceutical Co., Ltd.)), (YC 200 ㎎ / ㎏ and YC 400 ㎎ / ㎏), which were administered with 200 ㎎ / ㎏ and 400 ㎎ / ㎏ of extracts, respectively, and 9 mice were assigned to each group. Normal group was subcutaneously injected with only olive oil used as a base for testosterone administration. On the other hand, in order to induce enlargement of the prostate, olive oil prepared to have a testosterone concentration of 3 mg / ml in both the prostate hypertrophy group, the positive control group and the mixed extract administration group (200 mg / kg, 400 mg / Was subcutaneously injected at a dose of 3 mg / kg for 30 days. Thereafter, testosterone was injected subcutaneously into the prostate hypertrophy-induced group, the positive control group, and the mixed extract-administered group (200 mg / kg, 400 mg / kg) prepared in Example 1 to induce prostate hyperplasia At the same time, the normal control group and the prostate hypertrophy group were orally administered the purified water, and the positive control group was orally administered with finasteride at a concentration of 2 mg / ml at a dose of 10 mg / kg. In the mixed extract administration group prepared in Example 1, And 80 mg / ml were orally administered at a dose of 200 mg / kg and 400 mg / kg.

As a result, as shown in [Table 1] below, when the testosterone 3 mg / kg was administered subcutaneously to induce the enlargement of the prostate, the body weight began to decrease from 2 weeks after administration, and the final weight was about 20 %. On the other hand, prostate weight increased more than two times in the prostate hypertrophy group compared to the normal control group. In contrast, the prostate weight of prostate-treated group, finasteride, was significantly decreased by 31.43% compared to the prostate-hypertrophy group, and the dose of 200 mg / kg and 400 mg / kg was significantly decreased by 28.57% appear.

Weight (g) Prostate weight (g) % Inhibition first final first final Normal control group
NC) 359.44 + - 10.74 533.33 + - 31.22 1.14 ± 0.21 0.22 ± 0.05 Prostate hypertrophy
Trigger group
(BPH) 362.22 + - 6.67 444.44 + - 8.82 2.52 + - 0.24 0.57 ± 0.05 Positive control group
(Finasteride) 362.11 + - 7.82 441.11 + - 23.15 2.03 ± 0.22 * 0.46 0.06 * 31.43 Example 1
Mixed extract 200 mg / kg
Administered group
(YC 200 mg / kg) 360.00 + - 7.07 446.67 ± 27.39 2.05 ± 0.27 * 0.47 + 0.08 * 28.57 Example 1
Mixed extract 400 mg / kg
Administered group
(YC 400 mg / kg) 358.89 + - 10.54 443.75 + - 21.34 2.10 ± 0.27 * 0.47 ± 0.06 * 28.57

(Data expressed as mean ± SD (n = 9). *, Significant difference from the BPH value (ANOVA test, *, p <0.05).

< Experimental Example  2> Serum DHT  Measurement of concentration

The administration of the mixed extracts prepared in Example 1 is described in S. D. To determine the effect of DHT on blood DHT concentration in rats, Blood obtained by whole blood collection in the abdominal vein under the ether anesthesia was measured according to the user's instruction using an enzyme-linked immunoassay (ELISA) kit (ALPCO Diagnostics, Salem, NH, USA). The absorbance of an ELISA reader (Bio-Rad Laboratories, Inc.) was measured at 450 nm.

According to FIG. 1 showing the above measurement results, the blood DHT levels of the prostate hypertrophy group were significantly higher than those of the normal control group. However, the level of DHT in the positive control treated with finasteride was significantly lower than that in the prostate hypertrophy group. On the other hand, the DHT levels in the blood of the two administration groups (200 mg / kg of YC and 400 mg / kg of YC) administered with 200 mg / kg and 400 mg / kg of the mixed extracts prepared in Example 1, Of the patients with prostate hyperplasia.

That is, since the mixed extract according to the present invention has an effect of effectively lowering the DHT concentration in the blood, it can be effectively used for prophylactic and / or prophylactic treatment of androgenetic alopecia as well as enlargement of the prostate gland.

< Experimental Example  3> About prostate tissue Western blot

S.D. The testosterone 3 mg / kg was subcutaneously administered to the rats for 1 month to induce enlargement of the prostate gland 1 month later, and the positive control finasteride or the mixed extract prepared in Example 1 was administered 200 mg / Kg or 400 mg / kg, followed by lethal injection with ether, and the prostate gland was collected. The tissues were finely pulverized with a homogenizer and incubated in RIPA buffer (20 mM Tris, pH 7.4, 100 mM NaCl, 1% sodium deoxycholate, 1 mM) containing protease inhibitor (1 mM PMSF, 1 mM Na3VO4, 1 μg / ml leupeptine and 1 μg / ml aprotinin) % Nonidet P-40 and 1% SDS). The above solution was taken and subjected to western blotting. That is, a certain amount of protein was mixed with SDS-gel loading buffer and subjected to electrophoresis in SDS-acrylamide gel. Protein was transferred to PVDF membrane and blocked with Tris-buffered saline containing 5% skim milk. The membrane was reacted with anti-PCNA or GAPDH and reacted with an enhanced chemiluminescence reagent to identify each band.

As a result, as can be seen from FIG. 2, the positive control group showed a significantly increased PCNA compared with the normal control group, and the positive control group to which finasteride was administered or the mixed extract group prepared in Example 1 showed PCNA significantly Respectively. This is in agreement with the result that administration of finasteride or the mixed extract prepared in Example 1 suppressed the production of DHT in an experiment for measuring DHT concentration in blood, which is known as a substance causing prostate hyperplasia using ELISA in Experimental Example 3 .

< Experimental Example  4> Example  1, the effect of mixed extracts on liver and kidney metabolism

Blood biochemical indicators were obtained by collecting whole blood from the abdominal vein under ether anesthesia for 20-24 hours on the day before the autopsy and placing the blood in a centrifuge tube (SST-tube, BD micro vaccutainer, USA) Biochemical tests including alanine transaminase (ALT) and aspartate transaminase (AST) were performed on a serum biochemical analyzer (Hitachi-747, Hitachi Medical, Tokyo, Japan) for serum obtained by centrifugation (3,000 rpm × 15 min) Co., Ltd., Japan), and the reagents used were measured by DAIICHI (Daiichi chemical Co., Ltd., Japan). All experimental procedures and methods were performed according to the diagnostic guideline Respectively.

According to the results shown in the table below, the AST and ALT tend to increase in the prostate hypertrophy group compared with the normal control group, and there was a tendency that the HDL decreased and the LDL increased, . On the other hand, there was a slight decrease in TG, probably due to the relative increase in TG of the normal control group using olive oil as a vehicle. In the actual untreated group, TG was 21.25 ± 9.55 (data not shown) lower than that of the normal control group.

On the other hand, when 400 mg / kg of the mixed extract prepared in Example 1 was administered, AST, ALT and HDL were significantly decreased in comparison with the prostate hypertrophy group, and both of the normal control group, the prostate hypertrophy group and the positive control group AST was decreased compared with the control group. In particular, AST, TG and CRE were decreased compared to the control group administered with the Biclly alone at the dose of 400 mg / kg of the mixed extract prepared in Example 1. Thus, the mixed extract prepared in Example 1 seems to promote liver and kidney metabolism .

N. Control BPH Finasteride YC 200 mg / kg YC 400 mg / kg Mean STD Mean STD Mean STD Mean STD Mean STD AST 124.53 + - 18.44 2.65 ± 22.88 113.50 ± 16.30 * 124.59 ± 17.71 74.14 + - 8.22 ALT 30.14 ± 5.91 38.11 + - 6.58 29.69 + - 5.59 * 32.10 ± 6.91 27.08 + - 4.18 * T. Cho 62.96 8.35 49.27 + - 9.95 60.77 + - 10.94 61.67 ± 10.36 68.70 ± 18.24 HDL-C 20.82 + - 2.75 16.80 ± 2.32 19.04 + - 2.69 19.82 ± 2.96 * 23.05 + 3.87 * LDL-C 6.89 ± 1.32 9.68 ± 1.42 8.24 ± 1.27 10.08 + - 3.10 8.71 ± 2.30 TG 38.79 ± 13.14 17.48 ± 5.11 * 18.90 + - 4.90 18.08 ± 5.93 * 20.46 8.34 BUN 20.23 + - 2.39 19.96 ± 2.21 19.39 ± 2.69 20.33 + - 2.87 19.55 ± 1.93 CRE 0.57 + 0.11 0.53 ± 0.05 0.53 + 0.07 0.51 ± 0.06 0.49 + - 0.10

(Data expressed as mean ± SD (n = 9). *, Significant difference from the BPH value (ANOVA test, *, p <0.05).

< Experimental Example  5> Example  Pathological Study on the Effects of Mixed Extracts from Prostate on Histologic Changes

The last dose to the rat The next day after weighing and collecting, the prostate of the rat was surgically excised and its weight was measured. After weighing, each prostate was immersed in 10% neutral buffered formalin solution and dehydrated in 70%, 80%, 95%, and 100% ethanol successively, and paraffin blocks were made. Then, each prostate tissue was cut into a tubular shape with a thickness of 4 ㎛ using a microtome and then attached to a gelatin coated slide. The tissue sections were immersed in xylene for removal of paraffin and rehydrated in 100%, 95%, 80%, 70% ethanol and distilled water. Rehydrated tissues were stained with hematoxyline-eosin (H & E) and histologically evaluated under light microscope.

Histologic findings of H & E staining showed that the size of the prostate gland was larger in the normal group than in the other experimental groups, and the acinar gland was well preserved without rounding and duct epithelial cells, The normal nucleus and glands were in normal shape in the form of columnar type, and no proliferation or fibrosis of connective tissue was observed.

On the other hand, in the prostatic hypertrophy group, the lineage cells were irregularly distributed from linear to elliptical, and the ductal cells were also severely contracted in the form of squamous cells. The connective tissues were accompanied by severe cell proliferation and infiltration of lymphocytes and mononuclear cells Fibrotic degeneration and squamous cell carcinoma were observed in the area. On the other hand, finasteride-treated group, which was administered as a positive control, also had rounded morphology similar to that of the normal group. The ductal cells were well maintained in a columnar shape, and connective tissue showed proliferation of hardness and fibrosis. The results were similar.

In the mixed extract-treated group prepared in Example 1, the proliferation of the proliferated cells, which were observed in the normal control group, was more rounded, and the degree of atrophy was gentle in comparison with the prostatic hyperplasia group, indicating that even in the ductal and cubic cells, And space were observed to be gentle compared to the control group. In the connective tissue, lymphocyte and mononuclear infiltration decreased with hardness proliferation and fibrotic degeneration also tended to decrease compared to the prostate hypertrophy group.

< Experimental Example  6> Questionnaire about prostate function improvement

The severity of the disease in the enlarged prostate is judged by the use of a rheometer, prostate weight, and an assessment of the International Prostate Symptom Score (I-PSS), which is one of the indicators to assess the severity of lower urinary tract symptoms And the answers to the questions before and after the administration of the pill were scored using the I-PSS, which is an I-PSS, to confirm the improvement of the clinical symptoms accompanying the enlargement of the prostate. Specifically, according to the International Prostate Symptom Score Table (IPSS) in Table 3 below, the number of the relevant items is added together to obtain a score of "no symptom" (0), "mild symptom" (1-7) , 'Moderate symptoms' (8-19 points) or 'severe symptoms' (20-35 points).

Question Not at all
none 5 times
number 1 5 times
1-2 5 times
2-3 times 5 times
3-4 times almost
always 1. Do you feel that you still have urine even after you have seen it? 0 One 2 3 4 5 2. Do you occasionally urinate again within 2 hours of your usual urination? 0 One 2 3 4 5 3. Do you occasionally urinate when the urine is cut off when you urinate? 0 One 2 3 4 5 4. Are there occasions when it is difficult to tolerate regular urination? 0 One 2 3 4 5 5. Do you sometimes feel that your urine is thin? 0 One 2 3 4 5 6. Do you have to urinate your belly so that urine does not come out immediately when you urinate? 0 One 2 3 4 5 7. How many times a day do you usually wake up and urinate? none number 1 No.2 number 3 No. 4 More than 5 times

The present applicant measured the prostate index through the above-mentioned International Prostate Index Questionnaire for 104 spectators at the World Women's Invention Conference held from May 3, 2012 to May 6, 2012 at COEX.

The age distribution of 104 respondents was 10.5% in their 30s, 27.5% in their 40s, 32.5% in their 50s, 17.5% in their 60s, 10.00% in their 70s, and other 2.0% in their 40s and 60s. The highest rate. The reason for this is that the answers of the questionnaires are high in the 40s to 50s, and the period of the specific symptoms of the prostate enlargement seems to be in their 50s.

On the other hand, the average prostate index of these surgeons was 15.25 in the 30s, 9.0 in the 40s, 10.76 in the 50s, 14.28 in the 60s, and 6.25 in the 70s. The reason why the 30s were specifically high was because people who had prostate hypertrophy selectively responded to the questionnaire. The reason why the people in their 70s were relatively low was because they were very interested in health and self- Respectively. Thus, as can be seen from FIG. 3, the prostate gland index is estimated to be increased with increasing age when estimated in the 40s to 60s.

Therefore, the present inventors decided to administer the present composition to men and women (64% of all respondents) having a prostate index of 8 or more, which is considered to be in need of treatment, among the persons exhibiting symptoms of prostate enlargement in the 40s to 60s, The questionnaire was rewritten after 45 months of the men and women volunteered to take the composition with a prostate index of 8 or higher and the pill manufactured in Example 2 was administered for 1 month, The effects were analyzed.

All results were expressed as mean ± SD. Statistical analysis was performed using a one-way ANOVA test using SigmaStat ^® . The significance of the statistical analysis was as follows: *, p <0.05 and **, p <0.01 Respectively.

4, which shows the results of this experiment, the results of the comparison of the scores of the International Prostate Index Questionnaire before and after administration of the pill manufactured in Example 2 according to the present invention were 40, 50, 60 (*, P < 0.05) in all cases.

Claims (10)

A health food composition for preventing or ameliorating androgenetic alopecia comprising an extract of Yacon, casualties and a mixture of garlic extracts as an active ingredient. The health food composition according to claim 1, wherein the yacon is at least one selected from the group consisting of yacon leaves and yam corn root. The health food composition for prevention and improvement of androgenetic alopecia according to claim 1, which comprises a mixed extract of yacon, casualties, and seokchon in a weight ratio of 1 to 50: 1 to 25: 1 to 25 as an active ingredient . The health food for preventing or ameliorating androgenetic alopecia according to claim 1, which comprises, as an active ingredient, a mixed extract extracted from water, ethanol, methanol, propanol, ethyl acetate or a mixed solvent thereof as an extraction solvent Composition. The health food composition for preventing or improving androgenetic alopecia according to claim 1, which comprises, as an active ingredient, a mixed extract obtained by using 30 to 70% (v / v)% ethanol aqueous solution as an extraction solvent. A composition for health food for preventing or ameliorating the enlargement of the prostate gland, which comprises a mixed extract of yacon, casualty, and seokchangpo as an active ingredient. The health food composition according to claim 6, wherein the yacon is at least one selected from the group consisting of yacon leaves and yam corn root. The health food composition according to claim 6, wherein the active ingredient is a mixed extract having a blend weight ratio of 1: 50: 1 to 25: 1 to 25: yacon, casualties, and sorghum. The health food composition for preventing or improving enlargement of the prostate gland according to claim 6, which comprises, as an active ingredient, a mixed extract extracted from water, ethanol, methanol, propanol, ethyl acetate or a mixed solvent thereof as an extraction solvent . The health food composition according to claim 6, which comprises, as an active ingredient, a mixed extract extracted from (v / v) ethanol aqueous solution of 30 to 70% by weight as an extraction solvent.

Images